The Role of Deferiprone in Iron Chelation | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …

Abstract β-Thalassemia is one of the most common monogenetic diseases worldwide, with a
particularly high prevalence in the Middle East region. As such, we have developed long …

Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood
transfusions accumulate iron that damages the liver, endocrine system, and most importantly …

The aims of this review are to highlight the mechanisms and consequences of iron
distribution that are most relevant to transfused sickle cell disease (SCD) patients and to …

Many people with sickle cell disease (SCD) or other anemias require chronic blood
transfusions, which often causes iron overload that requires chelation therapy. The iron …

Introduction: Oxidative stress (caused by excess iron) can result in tissue damage, organ
failure and finally death, unless treated by iron chelators. The causative factor in the etiology …

Acute kidney injury (AKI) is a global health problem that occurs in a variety of clinical
settings. Despite some advances in supportive clinical care, no medicinal intervention has …

Purpose Iron chelation has improved survival and quality of life of patients with thalassemia
major. there are currently 3 commercially available iron-chelating drugs with different …

Objectives: Beta-thalassemias are a group of recessively autosomal inherited disorders of
hemoglobin synthesis, which, due to mutations of the beta-globin gene, lead to various …

Iron overload occurs when iron intake is increased over a sustained period of time, either as
a result of red blood cell transfusions or increased absorption of iron through the …